Atazanavir/cobicistat

Atazanavir/cobicistat (trade name Evotaz) is an antiretroviral medication used to treat and prevent HIV/AIDS. It is a fixed dose combination drug containing 300 mg of atazanavir and 150 mg of cobicistat.[1] Atazanavir is an HIV protease inhibitor and cobicistat blocks the body's metabolism of atazanavir by the enzyme CYP3A prolonging its effectiveness.

Atazanavir/cobicistat
Combination of
AtazanavirHIV protease inhibitor
CobicistatCytochrome P450 (CYP3A) inhibitor
Clinical data
Trade namesEvotaz
Identifiers
KEGG

It was approved by the Food and Drug Administration for use in United States in 2015.[2]

References
  1. "Evotaz Packing Insert" (PDF).
  2. "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz™ (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.